Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib in relapsed or refractory chronic lymphocytic leukemia patients

Next Previous
Trial Profile

Efficacy and safety of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib in relapsed or refractory chronic lymphocytic leukemia patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; JCAR 014
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 29 Jan 2019 New trial record
  • 04 Dec 2018 Results assessing safety and efficacy of ibrutinib in relapsed or refractory patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top